News & Updates

Early treatment with single- or double-dose ivermectin is no better than placebo in avoiding progression to hospitalization and in improving symptoms in mild COVID-19, results of a study have shown.

During the surge of the Omicron (B.1.1.529) variant, antiviral therapy with nirmatrelvir significantly reduced the rate of COVID-19-related hospitalization or death among patients aged ≥65 years, according to a recent study.

Reusable 3D-printed respirators offer a cost-effective alternative to N95 masks in providing protection against respiratory pathogens, such as SARS-CoV-2, suggests a recent study. In addition, fit testing results show that some 3D-printed mask designs appear to exceed the fit of N95 masks.

Patients who have been treated for tuberculosis appear to have an elevated risk of ischaemic stroke compared with their counterparts who have never had the infection, according to a study.

First-line treatment of ALK-positive non-small-cell lung cancer (NSCLC) with lorlatinib improves progression-free survival (PFS) and reduces central nervous system (CNS) progression vs crizotinib, regardless of presence or absence of baseline brain metastases (BM), a post hoc analysis of the phase III CROWN trial has shown.

The combination of tixagevimab and cilgavimab, two SARS-CoV-2 neutralizing monoclonal antibodies, appeared to protect against progression to severe disease or death in non-hospitalized, unvaccinated adults presenting with mild-to-moderate COVID-19, results of the ongoing phase III TACKLE trial showed.

Interstitial lung disease (ILD) rarely occurs in patients with systemic lupus erythematosus (SLE), but when it does, ILD is often associated with other systemic autoimmune disorders and may even significantly contribute to mortality, according to a study.

Low serum calcium in patients with acute pulmonary thromboembolism (PTE) independently predicts 30-day and long-term mortality, suggests a China study that used a new prognosis assessment model.

In the treatment of patients with severe COVID-19, adding the combination of pembrolizumab plus tocilizumab to standard of care (SOC) appears to result in higher and faster discharge from the hospital without sequelae, as shown in the proof-of-concept phase II COPERNICO trial.

In patients with chronic dependence on oral corticosteroids (OCS) for severe asthma, long-term exposure to dupilumab supports sustained reduction in OCS dosage and improvement in clinical outcomes for up to 96 weeks, according to an analysis of the phase III LIBERTY ASTHMA TRAVERSE study.